IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC) | MicrobiomeTrials← Back to trialsNCT06940440
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-01-27Est. Completion: 2027-04
Enrollment target: 9 participants Locations- H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
- University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Other microbiome trials you might be interested in
Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients …
Birmingham, United StatesEst. completion Dec 31, 2026
Advanced Solid TumorUnresectable Solid TumorClear Cell Renal Cell CarcinomaTriple Negative Breast Cancer
Non-Small Cell Lung Cancer Squamous
Non-Small Cell Lung Cancer Non-squamous
Colorectal Cancer (MSI-H)
Gastric Cancer
Cervical Cancer
Basal Cell Carcinoma
Bladder Cancer
Merkel Cell Carcinoma
Squamous Cell Carcinoma of Head and Neck
Cutaneous Squamous Cell Carcinoma
Pleural Mesothelioma
Esophageal Cancer
Endometrial Carcinoma
Solid Tumor
Solid Tumor, Adult
MSI-H Solid Malignant Tumor
Cancer With A High Tumor Mutational Burden
Epithelial Ovarian Carcinoma
Primary Peritoneal Cancer
Gastroesophageal Junction (GEJ) Cancer
Acral Melanoma
Mucosal Melanoma
Cutaneous Melanoma
DMMR Solid Malignant Tumor
Fallopian Tube Cancer
Ovarian Cancer
MSI-H Cancer
DMMR Cancer
Pancreas Adenocarcinoma (MSI-H)
Skin Cancer
Viral Cancer
Cervical Cancers
Endometrial Cancer
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, …
San Diego, United StatesEst. completion Nov 30, 2026